

Current Effective Date: 2/6/25

Status: Approved

Reviewed by Medical Policy Subcommittee: 8/3/17, 12/6/18, 5/5/22, 12/14/23, 2/6/25

Reviewed Dates: 8/3/17, 12/6/18, 5/5/22, 12/14/23

INSTRUCTIONS FOR USE DISCLAIMER:

SummaCare posts policies relating to coverage and medical necessity issues to assist members and providers in administering member benefits. These policies do not constitute a contract or agreement between SummaCare and any member or provider. The policies are guidelines only and are intended to assist members and providers with coverage issues. SummaCare is not a health care provider, does not provide or assist with health care services or treatment, and does not make guarantees as to the effectiveness of treatment administered by providers. The treatment of members is the sole responsibility of the treating provider, who is not an employee of SummaCare, but is an independent contractor in private practice. The policies posted to this site may be updated and are subject to change without prior notice to members or providers.

Medical policies in conjunction with other nationally recognized standards of care are used to make medical coverage decisions.

Implantable Wireless Pulmonary Pressure Monitor Policy - CardioMEMS™

Indication/Usage:

The CardioMEMS™ HF System provides pulmonary artery (PA) pressure remote monitoring using a small sensor. Permanently implanted in the distal pulmonary artery via a safe right heart catheterization procedure, the sensor measures changes in pulmonary artery pressure. These changes are a surrogate measure for fluid retention in the lungs caused by worsening heart failure.

Patient-initiated sensor readings, taken daily from their homes, are wirelessly transmitted to a secure website for clinicians to access and review. Directly monitoring PA pressure not only alerts you if a patient's heart failure is worsening, but it also allows you to intervene earlier, adjusting medication or making other treatment changes, often before a patient experiences any symptoms.

Patients who most commonly receive the CardioMEMS HF System are those on guideline directed medical therapy (GDMT) and those who exhibit any of the following:

- Fluid volumes that are hard to know or manage
- Challenging physical assessment
- Is a patient with HFpEF or HFrEF
- Compliant with heart failure medical care
- Would benefit from remote monitoring if they live far from a clinic

Medical Indications for Authorization Commercial and Medicare Members

SummaCare considers CardioMEMS (implantable wireless pulmonary artery pressure monitor) experimental and investigational for all indications due insufficient evidence of safety and efficacy.

CPT code

93264 remote monitoring code for CardioMEMS

There is currently no NCD or LCD per CMS

Limitations

CardioMEMS is used for hemodynamic monitoring is pulmonary artery (PA) catheters and central venous pressure catheters. They are invasive and inconsistent in predicting fluid responsiveness.

Coverage Decisions

Coverage decisions made per CMS, Hayes and industry standards research

Plans Covered By This Policy

Commercial and Medicare

Considered experimental and investigational for all lines of business

Sources Reviewed

Abraham, W. T. (2011a). Safety and accuracy of a wireless pulmonary artery pressure monitoring system in patients with heart failure. *American Heart Journal*, 558-566.

Abraham, W. T., & Jeffires, Bradley, MD, Yadav, Jay S, MD. (2011b). Wireless pulmonary artery hemodynamic monitoring in chronic heart failure: a randomized controlled trial. *The Lancet*, 658-666. Abraham WT, Stevenson LW, Bourge RC, Lindenfeld JA, Bauman JG, Adamson PB. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure

therapy: complete follow-up results from the champion randomized trial. *Lancet*. 2016; 387(10017):453-461.

Adamson PB, Abraham WT, Bourge RC, et al. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. *Circ Heart Fail*. 2014;7(6):935-944.

Adamson PB, Abraham WT, Stevenson LW, et al. Pulmonary artery pressure–guided heart failure management reduces 30-day readmissions. *Circ Heart Fail*. 2016;9(6):e002600. Benza RL, Raina A, Abraham WT, et al. Pulmonary hypertension related to left heart disease: insight from a wireless implantable hemodynamic monitor. *J Heart Lung Transplant*. 2015; 34(3):329- 33728.

Bourge RC, Abraham WT, Adamson PB, et al.; COMPASS-HF Study Group. Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: The COMPASS-HF study. *J Am Coll Cardiol*. 2008; 51(11):1073-1079. 52

Krum H. Telemonitoring of fluid status in heart failure: CHAMPION. *Lancet*. 2011; 377(9766):616- 618. 82.

Ollendorf DA, Sandhu AT, Chapman R, et al. CardioMEMS HF System (St. Jude Medical) and Sacubitril/Valsartan (Entresto, Novartis) for Management of Congestive Heart Failure: Effectiveness, Value, and Value-Based Price Benchmarks. Final Report. Prepared by the Institute for Clinical and Economic Review (ICER) for the California Technology Assessment Forum (CTAF). San Francisco, CA: CTAF; December 1, 2015.

Sandhu AT, Goldhaber-Fiebert JD, Owens DK, Turakhia MP, Kaiser DW, Heidenreich PA. Costeffectiveness of implantable pulmonary artery pressure monitoring in chronic heart failure. *JACC Heart Fail*. 2016;4(5):368-375

[HD10]